Ethics statement
A guardian of the patient provided written informed consent to
participate, and this study was approved by the University of British
Columbia Research Ethics Board as part of the
Personalized OncoGenomics trial (NCT02155621) and represents part of the
Personalized OncoGenomics trial NCT02155621.
Conflict of interest: The authors declare no competing
interests.
Acknowledgements: We gratefully acknowledge the participation
of the patient and their family. This work would not be possible without
the Personalized OncoGenomics (POG) team, Canada’s Michael Smith Genome
Sciences Centre technical and project management platforms along with
the generous support of the BC Cancer and BC Children’s Hospital
Foundations. The results published here are in part based upon data
generated by the Therapeutically Applicable Research to Generate
Effective Treatments (TARGET) initiative phs000218, managed by the NCI
available at https://portal.gdc.cancer.gov/, and the Treehouse Childhood
Cancer Initiative (https://treehousegenomics.soe.ucsc.edu/).
Information about TARGET can be found at
https://ocg.cancer.gov/programs/target.
Author contribution: AL, JT, YS, DR and SC wrote the
manuscript. AL and SC: collected clinical information. DR: performed
radiology review. JT: provided pathological analysis. YS: performed
bioinformatic analysis. DC, RR, RD and SC: provided patient treatment
and clinical care. All authors read and approved the final manuscript.
Data availability statement: Data supporting the findings of
this study are available from the corresponding author by request